Focused on developing treatments for retinal degenerative diseases, the company is a clinical‑stage biopharmaceutical developer advancing small‑molecule therapies that target vitamin A transport pathways. Its lead candidate, tinlarebant, is being studied for conditions such as Stargardt disease and ...
No congressional trades have been disclosed for Belite Bio, Inc (BLTE) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.